{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:15:01Z","timestamp":1789611301782,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151346","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T10:49:59Z","timestamp":1682938199000},"page":"151346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune Checkpoint Inhibitor\u2013Associated AKI: Debates in Diagnosis, Management, and Rechallenge"],"prefix":"10.1016","volume":"42","author":[{"given":"Harish","family":"Seethapathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6165","key":"10.1016\/j.semnephrol.2023.151346_bib0001","first-page":"1432","article-title":"Breakthrough of the year 2013","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Cancer immunotherapy. Science"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2023.151346_bib0002","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151346_bib0004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151346_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151346_bib0006","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/ijc.31993","article-title":"Epidemiology and outcomes of acute kidney injury in hospitalized cancer patients in China","volume":"144","author":"Cheng","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151346_bib0009","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151346_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252978","article-title":"Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study","volume":"16","author":"Koks","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0011","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0012","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1927313","article-title":"Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis","volume":"10","author":"Abdelrahim","year":"2021","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151346_bib0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151346_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.34067\/KID.0006752021","article-title":"Kidney injury in patients treated with immune checkpoint inhibitors does not meet KDIGO-AKI criteria","volume":"3","author":"Verploegen","year":"2022","journal-title":"Kidney360"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0016","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clgc.2022.01.017","article-title":"Chronic use of proton pump inhibitors is associated with an increased risk of immune checkpoint inhibitor colitis in renal cell carcinoma","volume":"20","author":"Yin","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0019","article-title":"The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151346_bib0020","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151346_bib0021","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CJI.0000000000000377","article-title":"Safety and clinical outcomes of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases","volume":"44","author":"Yeung","year":"2021","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151346_bib0022","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0023","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors","volume":"12","author":"Shimozaki","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151346_bib0024","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0025","article-title":"Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy","volume":"2018","author":"El Bitar","year":"2018","journal-title":"Case Rep Oncol Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0026","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ckj\/sfz051","article-title":"A new expression of immune checkpoint inhibitors\u2019 renal toxicity: when distal tubular acidosis precedes creatinine elevation","volume":"13","author":"Charmetant","year":"2020","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151346_bib0027","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-a report of 3 cases","volume":"2","author":"Herrmann","year":"2020","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151346_bib0028","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1053\/j.ajkd.2021.05.025","article-title":"Metabolic acidosis and hyponatremia in a patient with metastatic melanoma","volume":"78","author":"Adoor","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151346_bib0029","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151346_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151346_bib0031","first-page":"136","article-title":"Renal tubular acidosis and acute kidney injury secondary to cemiplimab","volume":"5","author":"Rashidi","year":"2021","journal-title":"J Onconephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151346_bib0032","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2017060643","article-title":"Extracellular adenosine stimulates vacuolar ATPase-dependent proton secretion in medullary intercalated cells","volume":"29","author":"Battistone","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151346_bib0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.kint.2016.08.029","article-title":"Purinergic signaling in kidney disease","volume":"91","author":"Menzies","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151346_bib0034","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.kint.2021.06.001","article-title":"Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System","volume":"100","author":"Wanchoo","year":"2021","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151346_bib0035","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.34067\/KID.0000132020","article-title":"Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor-associated acute kidney injury: CON","volume":"1","author":"Gutgarts","year":"2020","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0037","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151346_bib0038","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151346_bib0039","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0040","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0041","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165108","article-title":"Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis","author":"Singh","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0043","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0044","first-page":"112","article-title":"Renal injury in the setting of immune checkpoint inhibitor: report of a case of hypothyroidism and the role of positron emission tomography","volume":"4","author":"Heybeli","year":"2020","journal-title":"J Onconephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0045","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00330-022-09158-8","article-title":"Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases","volume":"33","author":"Awiwi","year":"2023","journal-title":"Eur Radiol"},{"issue":"28","key":"10.1016\/j.semnephrol.2023.151346_bib0046","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.semnephrol.2023.151346_bib0047","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.semnephrol.2023.151346_bib0048","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151346_bib0049","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151346_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151346_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005646","article-title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","volume":"10","author":"Gupta","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0053","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151346_bib0054","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151346_bib0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.34067\/KID.0003962021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?: PRO","volume":"3","author":"Herrmann","year":"2022","journal-title":"Kidney360"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151346_bib0056","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semnephrol.2023.151346_bib0057","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151346_bib0058","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151346_bib0059","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151346_bib0060","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151346_bib0061","doi-asserted-by":"crossref","DOI":"10.1053\/j.ackd.2021.09.002","article-title":"Transplant onconephrology in patients with kidney transplants","volume":"29","author":"Murakami","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151346_bib0062","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:41:03Z","timestamp":1759448463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000566"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151346","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor\u2013Associated AKI: Debates in Diagnosis, Management, and Rechallenge","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151346"}}